Drug Trial Radar · NCT06588855
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Dec 11, 2024
Primary completion
Oct 29, 2026
Study completion Jan 30, 2031
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Conditions
- Moderately to Severely Active Ulcerative Colitis
Interventions
AfimkibartDrug
Participants will receive afimkibart IV followed by afimkibart subcutaneous SC injection.
PlaceboDrug
Placebo matching IV afimkibart. Placebo matching SC afimkibart.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Clinical RemissionTime frame: At Week 12
Locations
168 sites in 29 countries. Site status is shown where the registry gives one.
Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan
Dothan, Alabama
Mayo Clinic Hospital
Scottsdale, Arizona
Arizona Digestive Health, P.C (ADH)
Sun City, Arizona
Om Research LLC
Apple Valley, California
Valley View Internal Medicine
Garden Grove, California
Gastro Care Associates
Lancaster, California
Stanford Medicine Outpatient Center
Redwood City, California
Peak Gastroenterology Associates
Colorado Springs, Colorado
Hi Tech and Global Research, LLC
Coral Gables, Florida
The Sister Life Research
Hialeah, Florida
LCC Medical Research Institute, LLC
Miami, Florida
Allied Biomedical Research Institute
Miami, Florida
Integrity Trials LLC
Orlando, Florida
Digestive and Liver Center of Florida
Orlando, Florida
Advanced Medical Research Center
Port Orange, Florida
University of South Florida School of Medicine Morsani Center for Advanced Health Care
Tampa, Florida
Guardian Angel Research Center, LLC
Tampa, Florida
Santos Research Center, CORP
Tampa, Florida
Cleveland Clinic Florida
Weston, Florida
Randomize Now, LLC
Atlanta, Georgia
Atlanta Gastroenterology Associates
Atlanta, Georgia
Gastroenterology Associates of Central Georgia
Macon, Georgia
Illinois Gastroenterology Group-Glenview powered by GI Alliance
Glenview, Illinois
GI Alliance - Gurnee
Gurnee, Illinois
Gastro Health Partners, LLC
New Albany, Indiana
Kansas Gastroenterology, LLC under Clinical Trials Network
Wichita, Kansas
One GI: GHP - Gastroenterology Health Partners Louisville
Louisville, Kentucky
Louisiana Research Center - GastroIntestinal Associates
Shreveport, Louisiana
Allied Gastrointestinal Associates, PA
Flowood, Mississippi
Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center
Lebanon, New Hampshire
Ellipsis Research Group
Brooklyn, New York
NYU Inflammatory Bowel Disease Center
New York, New York
Weill Cornell Medical College
New York, New York
DiGiovanna Inst for Med Ed&Res
North Massapequa, New York
Queens Village Medical Care
Queens Village, New York
Gastroenterology Group Of Rochester, LLP
Rochester, New York
Charlotte Gastroenterology and Hepatology, P.L.L.C
Charlotte, North Carolina
Omega Research North Carolina, LLC
Fuquay-Varina, North Carolina
Peters Medical Research (PMR), LLC
High Point, North Carolina
Dayton Gastroenterology, Inc.
Beavercreek, Ohio
Showing 40 of 168 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.